Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Bone Neoplasms
Interventions: RADIATION: Stereotactic Ablative Body Radiosurgery (SABR)|DRUG: MK-3475
Sponsor: Peter MacCallum Cancer Centre, Australia